Page 865 - Cardiac Nursing

0
6
6
/
/
0
2
009
009
/
/
2
qx
qx
d
41.
41.
41.
9
9
9
d
2
2
e 8
41
41
g
g
e 8
ar
a
a
Apt
Apt
ar
9:0
9:0
9:0
009
0
0
M
Pa
Pa
1 P
1 P
M
3-8
36_
K34
K34
K34
LWBK340-c36_p823-841.qxd 29/06/2009 09:01 PM Page 841 Aptara
36_
3-8
0-c
0-c
3-8
p82
p82
C HAPTER 3 6 / Lipid Management and Cardiovascular Disease 841
120. Grady, D., Herrington, D., Bittner, V., et al. (2002). Cardiovascular dis- 131. Muldoon, M. F., Manuck, S. B., & Matthews, K. A. (1990). Lowering
ease outcomes during 6.8 years of hormone therapy. Heart and Estro- cholesterol concentrations and mortality: A quantitative review of pri-
8
gen/replacement Study follow-up. JAMA, 288, 49–57. mary prevention trials. BMJ, 301, 309–314.
121. The Writing Group for the Women’s Health Initiative Investigators. 132. Schectman, G., McKinney, W. P., Pleuss, J., et al. (1990). Dietary intake
(2002). Risks and benefits of estrogen plus progestin in healthy post- of Americans reporting adherence to low cholesterol diet (NHANES II).
0
menopausal women. Principal results for the Women’s Health Initiative American Journal of Public Health, 80, 698–703.
0
Randomized Trial. JAMA, 288, 321–333. 133. Kashyap, M. L., McGovern, M. E., Berra, K., et al. (1999). Long-term
8
122. Fletcher, S. W., & Colditz, G. A. (2002). Failure of estrogen and prog- safety and efficacy of a once-daily niacin/lovastatin formulation for pa-
9
estin therapy for prevention. JAMA, 288, 366–368. tients with dyslipidemia. American Journal of Cardiology, 89, 672–678.
8
9
123. The Women’s Health Initiative Steering Committee. (2004). Effects of 134. Clark, R. W., Sutfin, T. A., Ruggeri, R. B., et al. (2004). Raising high-
conjugated equine estrogen in postmenopausal women with hysterec- density lipoprotein in humans through inhibition of cholesteryl ester
tomy. The Women’s Health Initiative Randomized Controlled Trial. transfer protein: An initial multidose study of torcetrapib. Arteriosclero-
4
4
JAMA, 291, 1701–1712. sis, Thrombosis, and Vascular Biology, 24, 490–497.
124. Mosca, L., Banka, C., Benjamin, E., et al. (2007). Evidence-based guide- 135. de Haan, W., de Vries-van der Weij, J., van der Hoorn, J. W., et al.
lines for cardiovascular disease prevention in women: 2007 Update. Cir- (2008). Torcetrapib does not reduce atherosclerosis beyond atorvastatin
5
culation, 115, 1481–1501. and induces more proinflammatory lesions than atorvastatin. Circula-
5
125. Brown, G., Albers, J. J., Fisher, L. D., et al. (1990). Regression of coro- tion, 117, 2515–2522.
7
7
nary artery disease as a result of intensive lipid-lowering therapy in men 136. Tobert, J. A. (1987). New developments in lipid-lowering therapy: The
with high levels of apolipoprotein B. New England Journal of Medicine, role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Cir-
6
6
323, 1289–1298. culation, 76, 534–538.
126. Haskell, W. L., Alderman, E. L., Fair, J. M., et al. (1994). Effects of in- 137. Gotto, A. M., & Pownall, H. J. (1992). Manual of lipid disorders. Balti-
tensive multiple risk reduction on coronary atherosclerosis and clinical more: Williams & Wilkins.
cardiac events in men and women with coronary artery disease. Circula- 138. Dujovne, C. A., Ettinger, M. P., McNeer, J. F., et al. (2002). Ezetimibe
9
9
tion, 89, 975–990. Study Group. Efficacy and safety of a potent new selective cholesterol ab-
127. Kane, J. P., Malloy, M. J., Ports, T. A., et al. (1990). Regression of coro- sorption inhibitor, ezetimibe, in patients with primary hypercholes-
nary atherosclerosis during treatment of familial hypercholesterolemia terolemia. American Journal of Cardiology, 90(10), 1092–1097.
4
with combined drug regimes. JAMA, 264, 3007–3012. 139. Sudhop, T., & von Bergmann, K. (2002). Cholesterol absorption in-
4
128. Watts, G. F., Lewis, B., Brunt, J. N., et al. (1992). Effects on coronary hibitors for the treatment of hypercholesterolemia. Drugs, 62(16),
artery disease of lipid lowering diet, or diet plus cholestyramine, in the 2333–2347.
9
St. Thomas’ Arteriosclerosis Regression Study (STARS). Lancet, 339, 140. Miller, N. H. (1997). Compliance with treatment regimens in chronic
9
2
2
563–569. asymptomatic diseases. American Journal of Medicine, 102, 43–49.
129. Hulley, S. B., Herman, T. B., Grady, D., et al. (1993). Should we be 141. Insull, W. (1997). The problem of compliance to cholesterol altering
9
measuring blood cholesterol levels in young adults? JAMA, 269, therapy. Journal of Internal Medicine, 241, 317–325.
1416–1419. 142. Berra, K., Miller, N. H., & Fair, J. M. (2006). Cardiovascular disease
130. Jacobs, D., Blackburn, H., Higgins, M., et al. (1992). The Conference prevention and disease management: A critical role for nursing. Journal
on Low Cholesterol: Mortality associations. Circulation, 86, 1046–1060. of Cardiopulmonary Rehabilitation, 26(4), 197–206.
6
6
6
6